Calvin Parker
Gerontology · Raleigh, NCNPI 1174116438
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Novo Nordisk at 33.5% of the total. 2025 is the largest year on record at $556, 7.9 times the $70 reported in 2022.
Across 46 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$291
- Otsuka America Pharmaceutical, Inc.$131
- AbbVie$98
- Lilly USA, LLC$66
- GSK$62
- Exact Sciences$57
- plus $162 from 7 others
What the payments were for
- Food & beverage$867100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $291 |
| Otsuka America Pharmaceutical, Inc. | 6 | $131 |
| AbbVie | 5 | $98 |
| Lilly USA, LLC | 4 | $66 |
| GSK | 3 | $62 |
| Exact Sciences | 3 | $57 |
| Amgen | 3 | $47 |
| Lundbeck LLC | 1 | $24 |
| AstraZeneca | 1 | $22 |
| Phadia US Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $18 |
| Merck | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
How this compares
$867 in reported general payments places this provider in the 75th percentile of 165 gerontology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 48 | $44,111 |
| OzempicSemaglutide | 40 | $42,382 |
| JardianceEmpagliflozin | 38 | $41,165 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $13,985 |
| MounjaroTirzepatide | 12 | $12,397 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $6,546 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $4,143 |
| Gabapentin | 162 | $2,334 |
| Megestrol Acetate | 30 | $1,992 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 66 | $1,986 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 93 | $1,856 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $1,619 |
| Ezetimibe | 84 | $1,415 |
| Metoprolol Succinate | 77 | $1,356 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 18 | $1,103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $291 | $42,38240 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $62 | $20,53126 claims |
| Lilly USA, LLCMounjaro | $66 | $12,39712 claims |
| AbbVieSynthroid | $98 | $57114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 165 gerontology providers in North Carolina.
Other gerontology in Raleigh
- Kimberly SmithRaleigh$10K
- Matthew WrenchRaleigh$2K
- Kelly AllenRaleigh$1K
- Pamela Harris ClaxtonRaleigh$625
- Sharon BibyGreensboro$22K
- Lora StephensStatesville$12K
- Michelle WoodCharlotte$9K
- Corinne NantzFuquay Varina$5K
- Taskeen MidgetteNew Bern$5K
- Brielle ReyesCary$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.